Clinical trial · Interventional
A Study of ABT-751 in Patients With Renal Cell Cancer
A Phase 2 Study of ABT-751 in Subjects With Refractory Colorectal Carcinoma
NCT00073112CI-TRIAL-00001005completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with renal cell cancer. Patients will receive ABT-751 by mouth daily for 21 days. Patients will be off drug for 7 days before starting the next cycle of drug.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Renal Cell Cancer | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ABT-751 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Objective Response Rate in subjects with RCC
- timeFrame
- 1 year
Secondary outcomes (3)
- measure
- Time to Tumor Progression (TTP)
- timeFrame
- 1 year
- measure
- Survival
- timeFrame
- 2 years
- measure
- Toxicities associated with treatment administration
- timeFrame
- 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria * Renal Cell Carcinoma. * Recurrent tumor. * At least 6 weeks post-nephrectomy. * Able to tolerate normal activities of daily living. * Adequate bone marrow, kidney, and liver function. Exclusion Criteria * Pregnant or breast feeding. * Anti-tumor therapy within 4 weeks of the start of ABT-751 administration. * CNS metastasis.
References
Publications (0)
Data not yet available
No reference posted for this study.